Aug 26 2019
BALTIMORE & MEMPHIS, Tennessee –(BUSINESS WIRE)–Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it has secured a financial sponsor to support its short-term and long-term growth as it closed on a round of growth capital from EW Healthcare Partners (“EW Healthcare”).
“We have known Cognate and followed its progress for a while and have been very impressed with the way in which the management team of Cognate has developed the business. Looking toward the future, the Company’s strategic plans are quite compelling and well aligned with our long term vision for the Company. We look forward to supporting the Cognate team as it continues to execute on its vision”, commented Evis Hursever, Managing Director of EW Healthcare.
Cognate is one of the only CDMOs capable of handling the volume of personalized products being approved by regulators today. The Company has commercial scale manufacturing capacity in Memphis, Tennessee to support products for both the E.U. and the U.S, and is continuing to expand its footprint to meet the needs of its clients and the market. The transaction includes significant growth capital to support Cognate’s commercial expansion that started in 2015.
“Cognate is delighted to be partnering with EW and its team to continue to expand our capacity and capabilities,” according to J. Kelly Ganjei, CEO of Cognate BioServices, Inc. “With EW as a new partner, in combination with our existing shareholders, we can remain focused on aggressive growth to meet the needs of the growing commercial markets in cellular therapies. We have a number of exciting service offerings and capabilities that we expect to be able to provide in the near future that will directly translate to the benefit of our clients and their patients.”
The capital raise and partnership with EW will further support Cognate’s commercial manufacturing infrastructure and scale up activities for its clients and prospects. This partnership with EW further secures the Company’s future as a leading CDMO in the commercialization of advanced cellular therapies such as car-T, NK cell, TIL, MIL and other cellular immunotherapy products.
About Cognate BioServices
Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development specializing in mid to late stage clinical trials and supporting our clients through product scale-up into commercial manufacturing. Cognate applies the knowledge and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish. www.cognatebioservices.com
About EW Healthcare Partners
With over $3 billion under management, EW Healthcare Partners is one of the largest and oldest growth equity firms pursuing investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York, and London. For more information, see www.ewhealthcare.com.
For Cognate BioServices
Scott Broughton, VP of Sales and Marketing